In this interview we discuss the goals of the Community Oncology Alliance, highlights from their annual meeting, and the challenge of transitioning cancer care to the hospital setting.
Practice & Policy
This video examines how a change to weight-based pembrolizumab dosing in first-line PD-L1–positive lung cancer could save nearly $1 billion in US healthcare costs.
The FDA has granted approval to pembrolizumab for pediatric and adult patients with microsatellite instability (MSI)-high or mismatch repair (MMR)-deficient solid tumors.
The implementation of the Affordable Care Act, which increased insurance coverage, was associated with an increase in the diagnosis of several screenable cancers at an earlier stage.
An NCCN survey taken during the period of congressional debate over new federal healthcare legislation, reports how oncology professionals feel about the possible repeal and replacement of the ACA.
Ultimately, meaningful value assessment is going to require unbiased comparisons between competing strategies. Decision models are extremely useful in this regard and can provide important insight into cost-effectiveness evaluations.
ASCO has released a statement announcing its opposition to President Trump’s budget outline for FY2018, which would cut about $6 billion in funding to the National Institutes of Health.
A cost-effectiveness analysis found that 9 weeks of trastuzumab therapy is better than the more standard 12 months in patients with HER2-positive breast cancer, without loss of clinical efficacy.
A study found that several disease- and treatment-specific factors are associated with an increased risk of near misses or safety incidents in patients undergoing radiation therapy.
Establishing a multidisciplinary oral chemotherapy clinic in a community hospital is feasible and could help reduce emergency department visits, recognize adverse events earlier, and improve staff and patient satisfaction.